Pre-irradiation semi-intensive chemotherapy with carboplatin and cyclophosphamide in malignant glioma: a phase II study

Anti-cancer Drugs
N ViñolasF Graus

Abstract

We undertook a phase II trial in 17 patients with malignant glioma and large measurable disease to assess response rate and survival with pre-irradiation chemotherapy, using higher doses than standard, trying to improve the outcome. Patients characteristics were: male/female 10/7, age 49 (range 23-59), median Karnofsky index 90% (range 70-100), glioblastoma multiforme/anaplastic astrocytoma 14/3. Treatment consisted of 2 cycles of carboplatin 200 mg/m(2) days 1-3 (or AUC x 8, total dose) plus cyclophosphamide 1000 mg/m(2) days 1-3. One partial response (6.5%) and two stabilizations (13.5%) were observed after pre-irradiation chemotherapy. Twelve out of 15 patients (80%) progressed after chemotherapy. Median survival time was 7.6 months and the survival at 1 year was 33%. Main toxicity was hematologic in the first cycle: neutropenia grade 4 in 100%; thrombocytopenia grade 4 in 73% and grade 3 in 27%; anemia grade 3 in 7%; in the second cycle: neutropenia and thrombocytopenia grade 4 in 100% and anemia grade 3 in 50%). No toxic death was related to treatment. This regimen showed limited activity in malignant glioma with large residual disease after surgery or biopsy.

References

Jul 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B JeremicL Mijatovic
Apr 1, 1991·Journal of Neuro-oncology·M PoissonJ Y Delattre
May 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W K YungM J Gleason
Jan 21, 1991·International Journal of Cancer. Journal International Du Cancer·J Clavel, S Cordier
Apr 1, 1990·Journal of Neurosurgery·D C LongeeS C Schold
Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R MacdonaldJ G Cairncross
Feb 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J R WoodW R Shapiro
Jun 1, 1985·Annals of Neurology·J G CairncrossR F DelMaestro
Nov 1, 1981·Journal of Neurosurgery·J C Allen, L Helson
Jan 1, 1981·Cancer·A B MillerA Winkler
Jan 1, 1994·Journal of Neuro-oncology·R E WarnickM K Malec
Aug 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R L HeidemanJ J Jenkins
May 1, 1996·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·S KirbyG Cairncross
Dec 1, 1996·American Journal of Clinical Oncology·M D PradosM Malec
May 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P A ForsythR J Sevick
Jul 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S A GrossmanS Piantadosi
Sep 19, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M R FetellS Piantadosi
Jul 1, 1999·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·B JeremicJ Aleksandrovic

❮ Previous
Next ❯

Citations

Jun 11, 2008·Current Neurology and Neuroscience Reports·Jaishri Blakeley
Aug 30, 2008·Neuro-oncology·Robert LustigUNKNOWN New Approaches to Brain Tumor Therapy CNS Consortium
Nov 7, 2013·European Journal of Radiology·Sellam KarunanithiChandrasekhar Bal
May 9, 2018·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·C BalañaS Villà
Aug 21, 2008·Journal of Neuro-oncology·Camilo E FadulJeffrey J Olson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.